Improving genetic education and testing for Black cancer survivors
Addressing Genomic Disparities in Cancer Survivors
This study is testing whether a chatbot can help Black cancer survivors learn more about genetic testing and encourage them to get tested compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 428 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 2 sites (Washington D.C., District of Columbia and 1 other locations) |
| Trial ID | NCT06073626 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance genetic education and increase requests for genetic testing among Black cancer survivors through a chatbot intervention compared to enhanced usual care. Participants will be randomly assigned to either the chatbot group or the usual care group, with the study evaluating engagement levels and psychosocial outcomes. The research will involve 428 Black cancer survivors who meet specific genetic testing criteria, focusing on their experiences and decision-making processes regarding genetic testing. The study seeks to address disparities in genetic testing utilization within this population.
Who should consider this trial
Good fit: Ideal candidates for this study are Black or African American cancer survivors aged 18-80 who are at least six months post-diagnosis of specific cancers and meet genetic testing eligibility criteria.
Not a fit: Patients who do not speak English, have previously undergone genetic testing, or lack internet access may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve access to genetic testing and education for Black cancer survivors, leading to better-informed health decisions.
How similar studies have performed: Other studies have shown success in using technology-based interventions to improve health education and outcomes, suggesting potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-80 years of age * Self-identify as Black or African American * At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic * Have not had genetic testing for hereditary cancer * Have received care at one of the participating sites in the prior five years * Meet National Comprehensive Cancer Network criteria for germline GT * Able to read and speak in English * Capable of providing informed consent * Have internet access (via smartphone, tablet or computer) * Comfortable using a computer or mobile phone independently to access information Exclusion Criteria: * Do not speak English * Unable to access the Internet * Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT) * Are unable to provide informed consent
Where this trial is running
Washington D.C., District of Columbia and 1 other locations
- Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States (Recruiting)
- Rutgers Cancer Institute — New Brunswick, New Jersey, United States (Recruiting)
Study contacts
- Principal investigator: Anita Y Kinney, PhD, RN — Director at Rutgers Cancer Institute
- Study coordinator: Erin Speiser, PhD, MA
- Email: erin.speiser@rutgers.edu
- Phone: 732-675-1668
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.